Lucid Diagnostics Inc. held its annual meeting of stockholders on June 24, 2026, with approximately 84.7% of outstanding shares represented. Stockholders approved an amendment to the certificate of incorporation to increase authorized common stock from 300,000,000 to 400,000,000 shares. Additionally, the meeting resulted in the re-election of Class B directors James L. Cox, M.D., John R. Palumbo, and Ronald M. Sparks, and the ratification of CBIZ CPAs P.C. as the independent accounting firm for the fiscal year ending December 31, 2025. Lucid Diagnostics Inc. is a medical technology company focused on diagnostic solutions.